Skip Navigation LinksHome > August 2012 - Volume 34 - Issue 6 > MYH9-related Disorders: Report on a Patient of Greek Origin...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e318257a64b
Original Articles

MYH9-related Disorders: Report on a Patient of Greek Origin Presenting With Macroscopic Hematuria and Presenile Cataract, Caused by an R1165C Mutation

Economou, Marina MD, PhD*; Batzios, Spyros P. MD, MSc*; Pecci, Alessandro MD, PhD; Printza, Nikoletta MD, PhD*; Savoia, Anna MD, PhD; Barozzi, Serena MD, PhD; Theodoridou, Stamatia MD, PhD; Teli, Aikaterini MD, PhD*; Psillas, Georgios MD, PhD§; Zafeiriou, Dimitrios I. MD, PhD*

Collapse Box

Abstract

Myosin heavy chain-9 (MYH9)-related disorders represent a heterogenous group of hereditary diseases caused by mutations in the gene encoding the heavy chain of nonmuscle myosin IIA. May-Hegglin anomaly and Fechtner, Sebastian, and Epstein syndromes are the four phenotypes of the disease, characterized by congenital macrothrombocytopenia and distinguished by different combinations of clinical signs that may include glomerulonephritis, sensorineural hearing loss, and presenile cataract. The spectrum of mutations responsible for the disease is wide and the existence of genotype-phenotype correlation remains a critical issue. We report the first case of an MYH9-RD in a patient of Greek origin presenting with macroscopic hematuria and presenile cataract caused by a p.R1165C mutation. The same mutation was present in the patient’s father, who exhibited no extrahematological features of the disease. The p.R1165C mutation is one of the MYH9 alterations whose prognostic significance is still poorly defined. Thus, the patients described add to the limited existing data on the MYH9 mutations and their resultant phenotypes.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.